TX-PURIFY-FUEL
5.2.2020 00:05:11 CET | Business Wire | Press release
Purify Fuel, Inc. (PFI), creator of the nanO2 Combustion Catalyst® that helps diesel consumers save money and reduce emissions, announced today that it has signed an exclusive distribution deal with Kanoo Blue. Purify Fuel’s nanO2 Combustion Catalyst optimizes performance and fuel efficiency in Marine Gasoil (MGO), making MGO a more cost-effective solution than Very Low Sulphur Fuel Oil (VLSFO).
Blending nanO2 Combustion Catalyst with MGO allows shipowners to avoid the compatibility issues associated with VLSFO blends and the mechanical challenges associated with running on multiple fuel types while increasing efficiency and saving money.
Further, with the recent implementation of IMO 2020’s sweeping legislation effective January 1, 2020, VLSFO prices have increased above MGO. While this trend may not hold, VLSFO pricing at/or near MGO reinforces the case for using Purify Fuel’s nanO2 Combustion Catalyst.
Through the agreement, Kanoo will act as the exclusive distribution partner in the region, helping customers in the marine, mining, oil services, transportation and power generation markets to achieve cleaner and more efficient diesel. Kanoo Blue focuses on identifying and bringing to its clients the best breakthrough technologies currently available in the world of science and technology across a wide spectrum of business segments.
“This partnership is not just good economically for the region, but it’s also great for environmental sustainability,” says Bader Abdulaziz Kanoo, Kanoo Blue Chairman. “Purify Fuel’s nanO2 Combustion Catalyst solution will help diesel engines work more efficiently while simultaneously helping to reduce harmful emissions. The timing for Purify Fuel could not be better as the region and the world search for cleaner fossil fuel options.”
“This deal builds on our first exclusive distribution partnership with Mencast Holdings, making Purify Fuel’s nanO2 Combustion Catalyst available in three of the world’s largest refueling ports — Singapore, Fujairah, and Shanghai — with annual sales of more than 20 billion gallons,” says John Carroll, CEO of Purify Fuel. “Additionally, through the efforts of our marine lead, John ‘Fozzie’ Miller, VADM (Ret), United States Navy, we are well on our way to meeting our goal of being distributed in 60% of the world’s largest ports.”
This exciting partnership will be on display at the Middle East Bunkering Convention , in Dubai. If you are a shipowner in the region and would like to learn more about how to leverage nanO2 to save money and reduce emissions, please contact us by visiting www.purifyfuel.com to schedule a meeting.
About Kanoo Blue:
Kanoo Blue was established in Bahrain for the purpose of bringing disruptive technologies to the Middle East and Africa, in the field of Energy, Nano Technology, Industrial IT, Artificial Intelligence, Bio-Technology, Water and other much needed high-end technologies to the region. Kanoo Blue is also the commercial partner for Houston Technologies, Middle-East for its portfolio of leading-edge disruptive technologies.
About Purify Fuel:
Purify Fuel creates patented nanotechnology-based rare earth oxides to help large diesel operators save money and reduce emissions. Purify Fuel’s nanO2 Combustion Catalysts® are custom blended to optimize diesel fuel and biodiesel blends for marine, fracking, military, mining, power generation, and rail markets. The combustion catalysts increase energy harvested from each gram of fuel while reducing particulate matter emissions and soot created by incomplete combustion. Purify Fuel works directly with large consumers of diesel and biodiesel fuel to help them save money, increase power, and reduce emissions.
For more information on Purify Fuel, please visit www.purifyfuel.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200204006069/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
